Manufacturer of Controlled Substances; Notice of Application; Apertus Pharmaceuticals, LLC, 35058 [2012-14165]
Download as PDF
<![CDATA[
35058
Federal Register / Vol. 77, No. 113 / Tuesday, June 12, 2012 / Notices
importer of the basic classes of
controlled substances listed.
DEPARTMENT OF LABOR
Office of the Secretary
Dated: June 5, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Agency Information Collection
Activities; Submission for OMB
Review; Comment Request; Pilot
Surveys of Employee Voice in the Coal
Mining Industry
[FR Doc. 2012–14163 Filed 6–11–12; 8:45 am]
BILLING CODE 4410–09–P
ACTION:
Notice.
The Department of Labor
(DOL) is submitting the Mine Safety and
Health Administration (MSHA)
sponsored new information collection
request (ICR) titled, ‘‘Pilot Surveys of
Employee Voice in the Coal Mining
Industry,’’ to the Office of Management
and Budget (OMB) for review and
approval for use in accordance with the
Paperwork Reduction Act (PRA) of 1995
(44 U.S.C. 3501 et seq.).
DATES: Submit comments on or before
July 12, 2012.
ADDRESSES: A copy of this ICR with
applicable supporting documentation;
including a description of the likely
respondents, proposed frequency of
response, and estimated total burden
may be obtained from the RegInfo.gov
Web site, https://www.reginfo.gov/
public/do/PRAMain, on the day
following publication of this notice or
by contacting Michel Smyth by
telephone at 202–693–4129 (this is not
a toll-free number) or sending an email
to DOL_PRA_PUBLIC@dol.gov.
Submit comments about this request
to the Office of Information and
Regulatory Affairs, Attn: OMB Desk
Officer for DOL–MSHA, Office of
Management and Budget, Room 10235,
New Executive Office Building,
Washington, DC 20503, Telephone:
202–395–6929/Fax: 202–395–6881
(these are not toll-free numbers), email:
OIRA_submission@omb.eop.gov.
FOR FURTHER INFORMATION CONTACT:
Michel Smyth by telephone at 202–693–
4129 (this is not a toll-free number) or
by email at DOL_PRA_PUBLIC@dol.gov.
SUPPLEMENTARY INFORMATION: The DOL
seeks OMB approval to conduct an
information collection as part of a pilot
study to determine how to measure
workers’ voice in mining workplaces
under the jurisdiction of the MSHA. The
DOL working definition for voice in the
workplace is workers’ ability to access
information on their rights in the
workplace, their understanding of those
rights, and their ability to exercise these
rights without fear of discrimination or
retaliation. Voice in the workplace is a
key outcome goal for the Secretary of
Labor and part of her vision of good jobs
for everyone. A separate concurrent
effort will measure workers’ voice in
SUMMARY:
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application;
Apertus Pharmaceuticals, LLC
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on March 27, 2012,
Apertus Pharmaceuticals, LLC, 331
Consort Drive, St Louis, Missouri 63011,
made application to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
Drug
Schedule
Alfentanil (9737) ...........................
Remifentanil (9739) ......................
Sufentanil (9740) ..........................
Fentanyl (9801) ............................
II
II
II
II
srobinson on DSK4SPTVN1PROD with NOTICES
The company plans to manufacture
small quantities of the listed controlled
substances to make reference standards
which will be distributed to their
customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than August 13, 2012.
Dated: June 4, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–14165 Filed 6–11–12; 8:45 am]
BILLING CODE 4410–09–P
VerDate Mar<15>2010
22:42 Jun 11, 2012
Jkt 226001
PO 00000
Frm 00126
Fmt 4703
Sfmt 4703
workplaces under the jurisdiction of the
Wage and Hour Division and
Occupational Safety and Health
Administration. Measuring voice among
miners, however, poses unique data
collection challenges, including
implementing a survey in a setting that
feels non-threatening to mine workers,
and asking questions in a format that
reflects mining community cultures and
practices. The DOL seeks to perform a
pilot study to investigate the efficacy of
different data collection methods and to
develop a survey instrument that is
appropriate for the mining community.
The primary research question is what
measures of voice and perceived noncompliance, combined with what modes
of data collection, could be best used to
track MSHA’s worker-protection
outreach activity? This ICR covers a set
two or three small-scale pilot data
collections. Data collection for this
effort will employ two or three
strategies: (1) Submission of paper
questionnaires to be filled out by
individual mine workers during offsite
mining-related training sessions, (2)
recruitment of miners by using radio
and paper advertisements, and (3) a
mail or phone survey. The DOL is
currently assessing the feasibility of
each method prior to implementation.
For example, implementation of a
phone or mail survey will depend on
the availability of a valid list of miners.
A maximum of 125 respondents will be
surveyed under each collection mode
for 375 maximum respondents for the
overall effort.
This information collection is subject
to the PRA. A Federal agency generally
cannot conduct or sponsor a collection
of information, and the public is
generally not required to respond to an
information collection, unless it is
approved by the OMB under the PRA
and displays a currently valid OMB
Control Number. In addition,
notwithstanding any other provisions of
law, no person shall generally be subject
to penalty for failing to comply with a
collection of information if the
collection of information does not
display a valid OMB Control Number.
See 5 CFR 1320.5(a) and 1320.6. For
additional information, see the related
notice published in the Federal Register
on January 19, 2012 (77 FR 2760).
Interested parties are encouraged to
send comments to the OMB, Office of
Information and Regulatory Affairs at
the address shown in the ADDRESSES
section within 30 days of publication of
this notice in the Federal Register. In
order to help ensure appropriate
consideration, comments should
reference OMB ICR Reference Number
201205–1219–001. The OMB is
E:\FR\FM\12JNN1.SGM
12JNN1
]]>Agencies
[Federal Register Volume 77, Number 113 (Tuesday, June 12, 2012)]
[Notices]
[Page 35058]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-14165]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application;
Apertus Pharmaceuticals, LLC
Pursuant to Sec. 1301.33(a), Title 21 of the Code of Federal
Regulations (CFR), this is notice that on March 27, 2012, Apertus
Pharmaceuticals, LLC, 331 Consort Drive, St Louis, Missouri 63011, made
application to the Drug Enforcement Administration (DEA) to be
registered as a bulk manufacturer of the following basic classes of
controlled substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Alfentanil (9737).......................... II
Remifentanil (9739)........................ II
Sufentanil (9740).......................... II
Fentanyl (9801)............................ II
------------------------------------------------------------------------
The company plans to manufacture small quantities of the listed
controlled substances to make reference standards which will be
distributed to their customers.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such substances, may file comments
or objections to the issuance of the proposed registration pursuant to
21 CFR 1301.33(a).
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than August 13, 2012.
Dated: June 4, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2012-14165 Filed 6-11-12; 8:45 am]
BILLING CODE 4410-09-P
